<DOC>
	<DOCNO>NCT01832116</DOCNO>
	<brief_summary>The purpose multicenter image sub study evaluate biodistribution organ pharmacokinetics 89Zr-MMOT0530A patient unresectable pancreatic platinum-resistant ovarian cancer . MMOT0530A monoclonal antibody target antigen overexpressed pancreatic ovarian cancer . Subsequent image 89Zr-MMOT0530A , patient treat DMOT4039A DMO4993g protocol ( clinicaltrials.gov identifier NCT01469793 ) study . DMOT4039A antibody-drug conjugate compose monoclonal antibody MMOT0530A mitotic agent monomethyl auristatin ( MMAE ) . By image patient monoclonal antibody MMOT0530A treatment , correlation tumor uptake 89Zr-MMOT0530A response DMOT4039A therapy assess .</brief_summary>
	<brief_title>89Zr-MMOT PET Imaging Pancreatic Ovarian Cancer Patients</brief_title>
	<detailed_description>A challenge current drug development use molecular target therapy high level heterogeneity present specific tumor type . The ability safely accurately predict presence absence target essential therapeutic effect newly develop drug . DMOT0439A one novel design molecular target drug ; antibody-drug conjugate compose monoclonal antibody MMOT0530A mitotic agent monomethyl auristatin ( MMAE ) . In DMO4993g protocol ( clinicaltrials.gov identifier NCT01469793 ) , safety efficacy DMOT4039A assess patient unresectable pancreatic platinum-resistant ovarian cancer . By perform 89Zr-MMOT0530A PET scan prior treatment DMOT4039A , uptake tracer primary metastatic tumor lesion evaluate . This likely provide important information target expression , whole body drug distribution correlation tumor uptake response therapy . Ultimately use 89Zr- MMOT0530A PET complimentary tool patient selection risk stratification evaluate . In part A study , optimal tracer dose 89Zr- MMOT0530A schedule PET imaging determine . In part B patient PET image treatment DMO4993g study dose time point assess part A .</detailed_description>
	<mesh_term>Neoplasms</mesh_term>
	<mesh_term>Ovarian Neoplasms</mesh_term>
	<mesh_term>Pancreatic Neoplasms</mesh_term>
	<mesh_term>Digestive System Diseases</mesh_term>
	<mesh_term>Gastrointestinal Diseases</mesh_term>
	<mesh_term>Pancreatic Diseases</mesh_term>
	<mesh_term>Digestive System Neoplasms</mesh_term>
	<mesh_term>Gastrointestinal Neoplasms</mesh_term>
	<mesh_term>Ovarian Diseases</mesh_term>
	<mesh_term>Adnexal Diseases</mesh_term>
	<criteria>Adult patient , &gt; /= 18 year age Eastern Cooperative Oncology Group ( ECOG ) performance status 0 1 Histologically document , incurable , locally advanced metastatic disease standard therapy exist , consist one following : Unresectable pancreatic ductal adenocarcinoma platinumresistant ovarian cancer Measureable disease , define least one bidimensionally measurable nonlymph node lesion &gt; /= 1 cm longaxis diameter spiral CT scan least one bidimensionally measurable lymph node measure &gt; /= 1.5 cm shortaxis diameter spiral CT scan Adequate hematological , renal liver function Exclusion criterion : Treatment antitumor therapy , include chemotherapy , biologic , experimental hormonal therapy , within 4 week prior Day 1 Known active infection Current Grade &gt; /= 2 toxicity ( except alopecia , anorexia fatigue ) prior therapy Grade &gt; /= 2 neuropathy Untreated active cerebral nervous system ( CNS ) metastases Pregnant breastfeed woman</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2014</verification_date>
	<keyword>Pancreatic cancer</keyword>
	<keyword>Ovarian cancer</keyword>
</DOC>